The treatment approach to cervix cancer has remained unchanged for several decades and new therapeutic strategies are now required to improve outcomes, as the prognosis is still poor. In the last years, a better understanding of HPV tumor–host immune system interactions and the development of new therapeutics targeting immune checkpoints generated interest in the use of immunotherapy in cervix cancer. Preliminary phase I–II trials demonstrated the efficacy, the duration of responses and the manageable safety of this approach. Currently, many phase II and III studies are ongoing in both locally advanced and metastatic cervical cancer, assessing immunotherapy as a single agent or in combination with chemotherapy and radiotherapy. We reviewed the published data and the therapeutic implications of the most promising novel immunotherapeutic agents under investigation in cervix cancer.

Immunotherapy in cervix cancer

Tuninetti V.;Pisano C.;Valabrega G.;
2020-01-01

Abstract

The treatment approach to cervix cancer has remained unchanged for several decades and new therapeutic strategies are now required to improve outcomes, as the prognosis is still poor. In the last years, a better understanding of HPV tumor–host immune system interactions and the development of new therapeutics targeting immune checkpoints generated interest in the use of immunotherapy in cervix cancer. Preliminary phase I–II trials demonstrated the efficacy, the duration of responses and the manageable safety of this approach. Currently, many phase II and III studies are ongoing in both locally advanced and metastatic cervical cancer, assessing immunotherapy as a single agent or in combination with chemotherapy and radiotherapy. We reviewed the published data and the therapeutic implications of the most promising novel immunotherapeutic agents under investigation in cervix cancer.
2020
Nov; 90
102088
102097
Cervix cancer; HPV; Immune checkpoint inhibitor; Immunotherapy; Antineoplastic Agents, Immunological; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; Humans; Neoplasm Staging; Randomized Controlled Trials as Topic; Uterine Cervical Neoplasms
Attademo L.; Tuninetti V.; Pisano C.; Cecere S.C.; Di Napoli M.; Tambaro R.; Valabrega G.; Musacchio L.; Setola S.V.; Piccirillo P.; Califano D.; Spina A.; Losito S.; Greggi S.; Pignata S.
File in questo prodotto:
File Dimensione Formato  
Attedemo et al, 2020.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 263.69 kB
Formato Adobe PDF
263.69 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1844974
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 30
  • ???jsp.display-item.citation.isi??? 29
social impact